| Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells H Du, K Hirabayashi, S Ahn, NP Kren, SA Montgomery, X Wang, ... Cancer cell 35 (2), 221-237. e8, 2019 | 392 | 2019 |
| IL-12 family cytokines in cancer and immunotherapy B Mirlekar, Y Pylayeva-Gupta Cancers 13 (2), 167, 2021 | 231 | 2021 |
| STING-induced regulatory B cells compromise NK function in cancer immunity S Li, B Mirlekar, BM Johnson, WJ Brickey, JA Wrobel, N Yang, D Song, ... Nature 610 (7931), 373-380, 2022 | 163 | 2022 |
| Regulatory B cells in cancer D Michaud, CR Steward, B Mirlekar, Y Pylayeva‐Gupta Immunological reviews 299 (1), 74-92, 2021 | 145 | 2021 |
| Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy B Mirlekar SAGE open medicine 10, 20503121211069012, 2022 | 142 | 2022 |
| B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer B Mirlekar, D Michaud, SJ Lee, NP Kren, C Harris, K Greene, ... Cancer immunology research 8 (3), 292-308, 2020 | 95 | 2020 |
| IL35 hinders endogenous antitumor T-cell immunity and responsiveness to immunotherapy in pancreatic cancer B Mirlekar, D Michaud, R Searcy, K Greene, Y Pylayeva-Gupta Cancer immunology research 6 (9), 1014-1024, 2018 | 62 | 2018 |
| Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity B Mirlekar, Y Wang, S Li, M Zhou, S Entwistle, T De Buysscher, ... Cell reports Medicine 3 (9), 2022 | 46 | 2022 |
| Co-expression of master transcription factors determines CD4+ T cell plasticity and functions in auto-inflammatory diseases B Mirlekar Immunology Letters 222, 58-66, 2020 | 32 | 2020 |
| Nuclear matrix protein SMAR1 control regulatory T-cell fate during inflammatory bowel disease (IBD) B Mirlekar, S Ghorai, M Khetmalas, R Bopanna, S Chattopadhyay Mucosal Immunology 8 (6), 1184-1200, 2015 | 31 | 2015 |
| B cell receptor signaling and protein kinase D2 support regulatory B cell function in pancreatic cancer D Michaud, B Mirlekar, C Steward, G Bishop, Y Pylayeva-Gupta Frontiers in immunology 12, 745873, 2022 | 21 | 2022 |
| Nuclear matrix binding protein SMAR1 regulates T-cell differentiation and allergic airway disease SV Chemmannur, AJ Badhwar, B Mirlekar, SK Malonia, M Gupta, ... Mucosal Immunology 8 (6), 1201-1211, 2015 | 20 | 2015 |
| Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3 D Michaud, B Mirlekar, S Bischoff, DO Cowley, DAA Vignali, ... Cytokine 125, 154817, 2020 | 14 | 2020 |
| Mycobacterium tuberculosis: approach to development of improved strategies for disease control through vaccination and immunodiagnosis B Mirlekar, S Pathak, G Pathade Indian J. Lepr 85 (2), 65, 2013 | 12 | 2013 |
| Chromatin remodeling protein SMAR1 is a critical regulator of T helper cell differentiation and inflammatory diseases B Mirlekar, D Gautam, S Chattopadhyay Frontiers in immunology 8, 72, 2017 | 10 | 2017 |
| MAR binding protein SMAR1 favors IL-10 mediated regulatory T cell function in acute colitis B Mirlekar, S Patil, R Bopanna, S Chattopadhyay Biochemical and Biophysical Research Communications 464 (2), 647-653, 2015 | 10 | 2015 |
| Carbon nanospheres mediated delivery of nuclear matrix protein SMAR1 to direct experimental autoimmune encephalomyelitis in mice SV Chemmannur, P Bhagat, B Mirlekar, KM Paknikar, S Chattopadhyay International Journal of Nanomedicine, 2039-2051, 2016 | 9 | 2016 |
| IL-35 Detection in B Cells at the mRNA and Protein Level B Mirlekar, D Michaud, Y Pylayeva-Gupta Regulatory B Cells: Methods and Protocols, 125-147, 2021 | 3 | 2021 |
| Impact of IL-23 in prostate cancer B Mirlekar Asian Journal of Andrology 24 (2), 223-224, 2022 | 2 | 2022 |
| IL-12 family cytokines in cancer and immunotherapy. Cancers. 2021; 13: 167 B Mirlekar, Y Pylayeva-Gupta s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in …, 2021 | 2 | 2021 |
